We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

121 hedge funds and large institutions have $431M invested in Theravance Biopharma in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 47 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

3% more funds holding

Funds holding: 118 → 121 (+3)

1.05% more ownership

Funds ownership: 98.55% → 99.61% (+1.1%)

4% less call options, than puts

Call options by funds: $22K | Put options by funds: $23K

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

22% less capital invested

Capital invested by funds: $552M → $431M (-$121M)

26% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 47

Holders
121
Holders Change
+3
Holders Change %
+2.54%
% of All Funds
1.74%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
19
Increased
35
Reduced
47
Closed
15
Calls
$22K
Puts
$23K
Net Calls
-$1K
Net Calls Change
-$2.38M

Top Buyers

1
CCM
Camber Capital Management
Massachusetts
+$9.27M
2
PWAM
Park West Asset Management
California
+$2.38M
3
Tudor Investment Corp
Tudor Investment Corp
Connecticut
+$1.55M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.52M
5
Marshall Wace
Marshall Wace
United Kingdom
+$1.5M

Top Sellers

1
BG
Baupost Group
Massachusetts
-$7.65M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$7.44M
3
BlackRock
BlackRock
New York
-$3.52M
4
Jane Street
Jane Street
New York
-$3.13M
5
NM
Newtyn Management
New York
-$2.37M
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
1
Weiss Asset Management
Massachusetts
$66.9M – – –
MAP
2
Madison Avenue Partners
New York
$62.9M – – –
BG
3
Baupost Group
Massachusetts
$59.1M -$7.65M -825,100 -11%
BlackRock
4
BlackRock
New York
$37.7M -$3.52M -379,497 -8%
ICM
5
Irenic Capital Management
New York
$24.8M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$24.1M -$7.44M -803,409 -23%
Pictet Asset Management
7
Pictet Asset Management
Switzerland
$18.4M -$1.16M -124,786 -6%
NM
8
Newtyn Management
New York
$14.7M -$2.37M -256,070 -13%
State Street
9
State Street
Massachusetts
$12.3M -$200K -21,533 -2%
OMC
10
Oasis Management Company
Cayman Islands
$10.4M +$1.4M +151,107 +15%
PWAM
11
Park West Asset Management
California
$10.4M +$2.38M +257,163 +29%
CCM
12
Camber Capital Management
Massachusetts
$8.97M +$9.27M +1,000,000 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$8.68M -$246K -26,548 -3%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$7.01M -$645K -69,623 -8%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$5M +$1.52M +163,951 +42%
Bank of America
16
Bank of America
North Carolina
$4.67M -$390K -42,038 -7%
Northern Trust
17
Northern Trust
Illinois
$4.38M -$307K -33,184 -6%
Morgan Stanley
18
Morgan Stanley
New York
$3.76M -$999K -107,785 -20%
Wellington Management Group
19
Wellington Management Group
Massachusetts
$2.97M +$406K +43,860 +15%
Charles Schwab
20
Charles Schwab
California
$2.79M -$32.5K -3,510 -1%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$2.14M +$976K +105,318 +79%
Goldman Sachs
22
Goldman Sachs
New York
$2M -$589K -63,541 -22%
SG Americas Securities
23
SG Americas Securities
New York
$1.88M +$115K +12,460 +6%
Macquarie Group
24
Macquarie Group
Australia
$1.87M – – –
C
25
Chescapmanager
Maryland
$1.81M -$263K -28,403 -12%
1
2 3 4 5

TBPH Hedge Fund Activity: Q1 2024 in Review

121 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2024, worth a combined $431M — down 22% from $552M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new TBPH positions and 15 closed out — a net gain of 4 holders — while 35 added to existing stakes and 47 trimmed.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $9.27M. The largest seller was Baupost Group, cutting an estimated $7.65M.

  • 121 institutional investors held Theravance Biopharma (TBPH) as of Q1 2024, up from 118 in Q4 2023.
  • Funds reported $431M of Theravance Biopharma stock for Q1 2024, down 22% quarter-over-quarter.
  • 19 funds opened new Theravance Biopharma positions in Q1 2024 and 15 closed out, a net change of +4 holders.
  • The largest Theravance Biopharma buyer in Q1 2024 was Camber Capital Management, an estimated $9.27M added.
  • The largest Theravance Biopharma seller in Q1 2024 was Baupost Group, an estimated $7.65M sold.

Based on aggregated 13F filings for Q1 2024.